MCID: HPT014
MIFTS: 49

Hepatorenal Syndrome

Categories: Rare diseases, Gastrointestinal diseases, Liver diseases, Nephrological diseases

Aliases & Classifications for Hepatorenal Syndrome

MalaCards integrated aliases for Hepatorenal Syndrome:

Name: Hepatorenal Syndrome 12 72 49 51 41 14 69
Hepato-Renal Syndrome 49

Classifications:



External Ids:

Disease Ontology 12 DOID:11823
ICD10 32 K76.7
ICD9CM 34 572.4
MeSH 41 D006530
NCIt 46 C113400
SNOMED-CT 64 51292008
UMLS 69 C0019212

Summaries for Hepatorenal Syndrome

NIH Rare Diseases : 49 Hepatorenal syndrome is a form of impaired kidney function that occurs in individuals with advanced chronic liver disease. As many as 40% of individuals with cirrhosis and ascites will develop hepatorenal syndrome. Symptoms may include fatigue, abdominal pain, and a general feeling of ill health (malaise). There are two distinct types of hepatorenal syndrome. Type I progresses quickly (within days), leading to kidney failure. Individuals with type I typically have dramatically reduced urine output, edema, and jaundice, and often suffer from hepatic encephalopathy. Type II progresses more slowly, over weeks or months, and the symptoms are less severe. The cause of hepatorenal syndrome is unknown. A contributing factor seems to be a narrowing of the blood vessels that connect into the kidneys. This causes a decrease in blood flow to the kidneys, impairing their function. In some cases, triggers or precipitating factors (infections, blood loss from the gastrointestinal tract, low blood pressure) are involved. Treatment is aimed at helping the liver work better and maintaining kidney function. In many cases, a liver transplant is needed. In some cases, individuals also need a kidney transplant.  Last updated: 7/13/2016

MalaCards based summary : Hepatorenal Syndrome, also known as hepato-renal syndrome, is related to hepatitis a and hepatic coma. An important gene associated with Hepatorenal Syndrome is ALB (Albumin), and among its related pathways/superpathways are FOXA2 and FOXA3 transcription factor networks and IL1 and megakaryocytes in obesity. The drugs Terlipressin and Adefovir Dipivoxil have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and skin, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia : 72 Hepatorenal syndrome (often abbreviated HRS) is a life-threatening medical condition that consists of... more...

Related Diseases for Hepatorenal Syndrome

Diseases related to Hepatorenal Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 173)
# Related Disease Score Top Affiliating Genes
1 hepatitis a 30.1 ALB F2
2 hepatic coma 30.1 ALB F2
3 esophageal varix 30.1 ALB F2
4 compartment syndrome 30.0 ALB F2
5 hepatopulmonary syndrome 30.0 ALB EDN1
6 acute liver failure 30.0 ALB F2
7 acute kidney tubular necrosis 29.9 ALB IL18 NPPA
8 portal hypertension 29.7 ALB EDN1 F2
9 eclampsia 29.7 ALB EDN1 F2
10 obstructive jaundice 29.6 ALB EDN1 F2 REN
11 pulmonary edema 29.1 ACE EDN1 F2 REN
12 pulmonary hypertension 28.9 ACE EDN1 NPPA REN
13 liver cirrhosis 28.5 ALB AQP2 EDN1 F2 NPPA REN
14 pre-eclampsia 28.5 CST3 EDN1 F2 NPPA REN
15 peroxisome biogenesis disorder 1a 11.1
16 joubert syndrome with oculorenal anomalies 11.1
17 benign essential hypertension 10.5 ALB REN
18 kidney papillary necrosis 10.5 ALB REN
19 malignant renovascular hypertension 10.4 EDN1 REN
20 antipyrine metabolism 10.4 ALB F2
21 non-a-e hepatitis 10.4 ALB F2
22 malignant secondary hypertension 10.4 EDN1 REN
23 fournier gangrene 10.4 ALB F2
24 perinephritis 10.4 EDN1 REN
25 abdominal tuberculosis 10.4 ALB F2
26 kwashiorkor 10.4 ALB F2
27 hepatic tuberculosis 10.4 ALB F2
28 intestinal impaction 10.4 F2 REN
29 suprasellar meningioma 10.4 F2 REN
30 splenic disease 10.4 ALB F2
31 renal tuberculosis 10.4 EDN1 REN
32 ascending cholangitis 10.4 ALB F2
33 cardiac tamponade 10.4 F2 REN
34 hypersplenism 10.4 ALB F2
35 hemorrhagic fever 10.4 ALB F2
36 choledocholithiasis 10.4 ALB F2
37 analbuminemia 10.4 ALB F2
38 hepatitis 10.3
39 apnea, obstructive sleep 10.3 EDN1 REN
40 dysfibrinogenemia 10.3 ALB F2
41 hyporeninemic hypoaldosteronism 10.3 ACE REN
42 hepatitis e 10.3 ALB F2
43 renal artery obstruction 10.3 ACE REN
44 vein disease 10.3 ALB F2
45 hypertension, diastolic 10.3 ACE REN
46 atrial septal defect 4 10.3 ACE REN
47 hypertensive retinopathy 10.3 ACE REN
48 noma 10.3 ALB IL18
49 hypertensive nephropathy 10.3 ACE ALB
50 bile duct disease 10.3 ALB F2

Comorbidity relations with Hepatorenal Syndrome via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alcoholic Liver Cirrhosis
Chronic Kidney Failure Deficiency Anemia
Heart Disease Hepatic Encephalopathy
Portal Hypertension

Graphical network of the top 20 diseases related to Hepatorenal Syndrome:



Diseases related to Hepatorenal Syndrome

Symptoms & Phenotypes for Hepatorenal Syndrome

MGI Mouse Phenotypes related to Hepatorenal Syndrome:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.91 ACE ALB AQP2 CST3 EDN1 F2
2 cardiovascular system MP:0005385 9.87 ACE CST3 EDN1 F2 IL18 NPPA
3 mortality/aging MP:0010768 9.76 ACE ALB AQP2 CST3 EDN1 F2
4 muscle MP:0005369 9.43 CST3 EDN1 IL18 NPPA REN ALB
5 renal/urinary system MP:0005367 9.1 ACE ALB AQP2 EDN1 NPPA REN

Drugs & Therapeutics for Hepatorenal Syndrome

Drugs for Hepatorenal Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Terlipressin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 14636-12-5 72081
2
Adefovir Dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
3
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
4
Norfloxacin Approved Phase 4 70458-96-7 4539
5
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
6
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
7
Tranexamic Acid Approved Phase 4 1197-18-8 5526
8 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Phase 1
9 Coagulants Phase 4,Phase 2,Phase 3,Phase 1
10 Hemostatics Phase 4,Phase 2,Phase 3,Phase 1
11 Lypressin Phase 4,Phase 2,Phase 3,Phase 1
12 Natriuretic Agents Phase 4,Phase 2,Phase 3,Phase 1
13 Vasoconstrictor Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
14 Adefovir Phase 4
15 Anti-Infective Agents Phase 4,Phase 3,Phase 2
16 Anti-Retroviral Agents Phase 4
17 Antiviral Agents Phase 4,Phase 2
18 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
19 Nucleic Acid Synthesis Inhibitors Phase 4
20 Reverse Transcriptase Inhibitors Phase 4
21 Adrenergic Agents Phase 4,Phase 3,Phase 2,Early Phase 1
22 Adrenergic Antagonists Phase 4,Phase 3
23 Adrenergic beta-Antagonists Phase 4,Phase 3
24 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Early Phase 1
25 Vasodilator Agents Phase 4,Phase 3
26 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3
27 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
28 Cytochrome P-450 Enzyme Inhibitors Phase 4
29 Topoisomerase Inhibitors Phase 4
30 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3
31 Adrenergic alpha-1 Receptor Antagonists Phase 4
32 Adrenergic alpha-Antagonists Phase 4
33 Anticoagulants Phase 4
34 Antifibrinolytic Agents Phase 4
35 Blood Substitutes Phase 4
36 Dextrans Phase 4
37 Plasma Substitutes Phase 4
38
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
39
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
40
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
41
Propranolol Approved, Investigational Phase 3 525-66-6 4946
42
Midodrine Approved Phase 2, Phase 3 42794-76-3, 133163-28-7 4195
43
Octreotide Approved, Investigational Phase 2, Phase 3 83150-76-9 6400441 383414
44
Norepinephrine Approved Phase 3,Phase 2,Early Phase 1 51-41-2 439260
45
Mannitol Approved, Investigational Phase 3 69-65-8 6251 453
46
Dopamine Approved Phase 2, Phase 3 51-61-6, 62-31-7 681
47
Furosemide Approved, Vet_approved Phase 2, Phase 3 54-31-9 3440
48
Spironolactone Approved Phase 2, Phase 3 1952-01-7, 52-01-7 5833
49
Tolvaptan Approved Phase 2, Phase 3 150683-30-0 216237
50
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1

Interventional clinical trials:

(show top 50) (show all 74)

# Name Status NCT ID Phase Drugs
1 The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure Unknown status NCT02489864 Phase 4 Terlipressin
2 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
3 Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis Completed NCT00359853 Phase 4 Oral norfloxacin
4 Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention Completed NCT01542801 Phase 4 Norfloxacin;ciprofloxacin
5 Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS Recruiting NCT02925975 Phase 4 Carvedilol
6 Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response Active, not recruiting NCT01530711 Phase 4 Terlipressin and albumin
7 Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding Not yet recruiting NCT03023189 Phase 4 Tranexamic acid;Placebo
8 Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin Suspended NCT00287664 Phase 4 terlipressin
9 The INFECIR-2 Albumin Prevention Study Terminated NCT02034279 Phase 4 Albumin
10 Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis Terminated NCT00570960 Phase 4 Dextran 70
11 Terlipressin Given As I.V. Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome Unknown status NCT00742690 Phase 2, Phase 3 terlipressin given by intravenous boluses and albumin;terlipressin given by continuous intravenous infusion and albumin
12 Short-term Survival in Patients With Severe Alcoholic Hepatitis Treated With Steroid Versus Pentoxifylline Unknown status NCT01455337 Phase 3 pentoxifylline;Prednisolone
13 To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Unknown status NCT02649335 Phase 3 Propranolol
14 Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1 Completed NCT00089570 Phase 3 terlipressin;Placebo
15 Noradrenalin vs Terlipressin in Hepatorenal Syndrome Completed NCT00370253 Phase 3 Terlipressin;Noradrenalin
16 A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin Completed NCT01143246 Phase 3 Terlipressin;Placebo
17 TYPE 2 HEPATORENAL SYNDROME Completed NCT01637454 Phase 3 Noradrenaline;Terlipressin
18 The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction Completed NCT00240045 Phase 2, Phase 3 Midodrine, albumin, octreotide LAR;midodrine, octreotide, albumin
19 Terlipressin in Septic Shock in Cirrhosis Completed NCT00628160 Phase 2, Phase 3 Terlipressin;alpha adrenergic drugs
20 Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites Completed NCT02173288 Phase 2, Phase 3 Standard medical therapy;Tolvaptan;Midodrine
21 Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection. Completed NCT00502086 Phase 3
22 Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study Completed NCT02451033 Phase 2, Phase 3 standard medical therapy;G-CSF;Growth Hormone
23 CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment Completed NCT00604357 Phase 3 anti-CD 25 mAb, Sirolimus, MMF
24 Double-blind Randomized Controlled Trial in Severe Alcoholic Hepatitis Completed NCT01214226 Phase 3 Pentoxifylline;placebo
25 A Study To Confirm Efficacy and Safety of Terlipressin in HRS Type 1 Recruiting NCT02770716 Phase 3 Terlipressin acetate
26 Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction Recruiting NCT01453218 Phase 3 ATeGe-Fresenius
27 Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone Recruiting NCT02281929 Phase 3 Amoxicillin;Placebo;Prednisolone
28 Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome Terminated NCT00742339 Phase 2, Phase 3 Terlipressin plus albumin;Midodrine plus octreotide plus human albumin
29 Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE Withdrawn NCT00787436 Phase 3 Thalidomide
30 Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure Unknown status NCT01587222 Phase 2 Albumin;Midodrine;Octreotide
31 Low-dose Albumin Solution in SBP: a Randomized Double-blind Pilot Study Unknown status NCT00852800 Phase 2 Albumin;Albumin
32 Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Hydrocortisone on Renal and Haemodynamic Function Unknown status NCT00657306 Phase 2 hydrocortisone;dextrose solution 5%
33 Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients Completed NCT01436500 Phase 2 Ifetroban Injection;Placebo
34 A Study of Terlipressin in Patients With Hepatorenal Syndrome Type 1 Completed NCT01373606 Phase 1, Phase 2 Terlipressin
35 Single Pass Albumin Dialysis in Patients With Cirrhosis Completed NCT00764049 Phase 1, Phase 2
36 A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis Completed NCT00562783 Phase 2 Vitaliver;Placebo
37 The Efficacy and Safety of Entecavir Treatment of Patients With Acute on Chronic Hepatitis B Liver Failure Completed NCT01254994 Phase 2 entecavir;Traditional comprehensive medical treatment
38 Midodrine and Albumin for Cirrhotic Patients With Functional Renal Impairment Completed NCT01133795 Phase 2 Midodrine plus Albumin
39 Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH) Active, not recruiting NCT02854631 Phase 2 Selonsertib;Prednisolone;Placebo
40 UC-MSC Infusion for HBV-Related Acute-on-Chronic Liver Failure Not yet recruiting NCT02812121 Phase 2 umbilical cord blood mesenchymal stem cells
41 A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome Terminated NCT01906307 Phase 1 LJPC-501
42 Evaluation of Renal Blood Flow Using Contrast Enhanced Ultrasound for Differential Diagnosis of Acute Kidney Injury in Cirrhotic Patients: A Pilot Study Unknown status NCT02147470 Definity ultrasound contrast agent
43 Prognosis Scoring System for Acute-on-Chronic Liver Failure Unknown status NCT01961440
44 Treatment of Type-1 Hepatorenal Syndrome Associated With Sepsis Completed NCT01932151 Terlipressin and albumin
45 Outcomes of Renal Function in Hepatorenal Syndrome (HRS) Determined By Comparison of Target Mean Arterial Pressure (MAP) of 65 - 70 Mmhg Versus ≥ 85 Mmhg Completed NCT02789150 Early Phase 1 Norepinephrine (Levophed);Norepinephrine (Levophed)
46 Plasma and Hemodynamic Markers During Hepatectomy Completed NCT01700231
47 To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure Completed NCT02573727 Nor adrenaline + albumin;Terlipressin + albumin
48 Evaluation of Probiotics in the Treatment of Portal Hypertension Completed NCT00831337
49 Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Acute-On-Chronic Liver Failure. Completed NCT02467348 Albumin;Ascitic fluid
50 To Study The Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction in Decompensated Cirrhotics Undergoing Less Than 5 Litres Of Ascitic Fluid Tap With Or Without Albumin Infusion. Completed NCT02467322 Albumin;ascitic fluid

Search NIH Clinical Center for Hepatorenal Syndrome

Cochrane evidence based reviews: hepatorenal syndrome

Genetic Tests for Hepatorenal Syndrome

Anatomical Context for Hepatorenal Syndrome

MalaCards organs/tissues related to Hepatorenal Syndrome:

38
Liver, Kidney, Skin, Bone, Bone Marrow, Neutrophil, Breast

Publications for Hepatorenal Syndrome

Articles related to Hepatorenal Syndrome:

(show top 50) (show all 625)
# Title Authors Year
1
Circulating miR-21, miR-210 and miR-146a as potential biomarkers to differentiate acute tubular necrosis from hepatorenal syndrome in patients with liver cirrhosis: a pilot study. ( 29303765 )
2018
2
Hepatorenal syndrome: the clinical impact of vasoactive therapy. ( 29258378 )
2018
3
Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. ( 29391267 )
2018
4
Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis. ( 29422242 )
2018
5
Systemic hemodynamic response to terlipressin predicts development of hepatorenal syndrome and survival in advanced cirrhosis. ( 29432366 )
2018
6
Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. ( 28052382 )
2017
7
Editorial: tackling hepatorenal syndrome-terlipressin for all, or time for a stratified approach? ( 28621082 )
2017
8
Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. ( 28763340 )
2017
9
Vasoactive Agents for Hepatorenal Syndrome: A Mixed Treatment Comparison Network Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials. ( 28924736 )
2017
10
The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States. ( 28509578 )
2017
11
Acute kidney injury in acute-on-chronic liver failure: where does hepatorenal syndrome fit? ( 28844314 )
2017
12
Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. ( 28533910 )
2017
13
Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome. ( 28902040 )
2017
14
Portopulmonary hypertension and hepatorenal syndrome. Two faces of the same coin. ( 28583409 )
2017
15
A Case of Hepatorenal Syndrome and Abdominal Compartment Syndrome with High Renal Congestion. ( 28919595 )
2017
16
Hepatorenal Syndrome ( 28613606 )
2017
17
Terlipressin for hepatorenal syndrome: ready for prime time. ( 28403987 )
2017
18
New Developments in Hepatorenal Syndrome. ( 28602971 )
2017
19
Baclofen-Related Neurotoxicity: Implication in a Fatality Associated With Hepatorenal Syndrome. ( 28680269 )
2017
20
Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. ( 28403995 )
2017
21
Noradrenaline as an alternative medical treatment to terlipressin in the management of hepatorenal syndrome type 1. ( 29054321 )
2017
22
Induction of renal artery hyperresponsiveness by alpha1-adrenoceptor in hepatorenal syndrome. ( 29312606 )
2017
23
Association of arginine vasopressin receptor 1a gene polymorphisms with hepatorenal syndrome. ( 28420919 )
2017
24
Bile Cast Nephropathy in Patients with Acute Kidney Injury Due to Hepatorenal Syndrome: A Postmortem Kidney Biopsy Study. ( 28660146 )
2017
25
Hepatorenal syndrome: role of the transjugular intrahepatic stent shunt in real life practice. ( 29151800 )
2017
26
Comparative efficacy of vasoconstrictor therapies for type 1 hepatorenal syndrome: a network meta-analysis. ( 28708431 )
2017
27
Protective Effects of the Third Generation Vasodilatory I9eta - Blocker Nebivolol against D-Galactosamine - Induced Hepatorenal Syndrome in Rats. ( 29362613 )
2017
28
Terlipressin versus other vasoactive drugs for hepatorenal syndrome. ( 28953318 )
2017
29
Pharmacological Therapies for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis. ( 28991106 )
2017
30
Terlipressin is superior to midodrine/octreotide for hepatorenal syndrome type 1. ( 29111999 )
2017
31
Management of ascites and hepatorenal syndrome. ( 28836115 )
2017
32
Acute kidney injury in cirrhosis besides hepatorenal syndrome. ( 27727684 )
2016
33
Is MELD score failing patients with liver disease and hepatorenal syndrome? ( 27721921 )
2016
34
Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus. ( 27660674 )
2016
35
TERLIPRESSIN VERSUS NORADRENALINE FOR HEPATORENAL SYNDROME. Economic evaluation under the perspective of the Brazilian Public Health System. ( 27305421 )
2016
36
Management of Hepatorenal Syndrome in the Era of Acute-on-Chronic Liver Failure: Telipressin and Beyond. ( 27133393 )
2016
37
Population Based Trends in the Incidence of Hospital Admission for the Diagnosis of Hepatorenal Syndrome: 1998-2011. ( 27144022 )
2016
38
Association of eNOS Gene Polymorphisms G894T and T-786C with Risk of Hepatorenal Syndrome. ( 27594880 )
2016
39
Hepatorenal syndrome. ( 27372112 )
2016
40
Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. ( 26659927 )
2016
41
Outcomes of liver transplantation in patients with hepatorenal syndrome. ( 27648152 )
2016
42
Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis. ( 27876501 )
2016
43
Influence of hepatorenal syndrome on outcome of living donor liver transplantation: A single-center experience in 357 patients. ( 27323334 )
2016
44
Clinical Scenarios in Acute Kidney Injury: Hepatorenal Syndrome. ( 27169751 )
2016
45
Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation. ( 26649801 )
2016
46
Evidence-Based Therapeutic Options for Hepatorenal Syndrome. ( 26922867 )
2016
47
Hepatorenal syndrome in cirrhosis: diagnostic, pathophysiological, and therapeutic aspects. ( 27248461 )
2016
48
Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: Implications for its safety profile. ( 27586252 )
2016
49
Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis. ( 27655104 )
2016
50
Fractional excretion of sodium in hepatorenal syndrome: Clinical and pathological correlation. ( 28008340 )
2016

Variations for Hepatorenal Syndrome

Expression for Hepatorenal Syndrome

Search GEO for disease gene expression data for Hepatorenal Syndrome.

Pathways for Hepatorenal Syndrome

Pathways related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.8 ALB F2
2 10.35 F2 IL18
3 9.98 ACE CST3

GO Terms for Hepatorenal Syndrome

Cellular components related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 ACE ALB CST3 EDN1 F2 IL18
2 endoplasmic reticulum lumen GO:0005788 9.33 ALB CST3 F2
3 extracellular space GO:0005615 9.23 ACE ALB CST3 EDN1 F2 IL18

Biological processes related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.63 CST3 EDN1 NPPA
2 regulation of receptor activity GO:0010469 9.62 EDN1 F2 IL18 NPPA
3 negative regulation of proteolysis GO:0045861 9.49 CST3 F2
4 regulation of vasoconstriction GO:0019229 9.48 ACE EDN1
5 positive regulation of heart rate GO:0010460 9.43 EDN1 NPPA
6 regulation of blood vessel size GO:0050880 9.4 EDN1 NPPA
7 response to muscle stretch GO:0035994 9.37 EDN1 NPPA
8 amyloid-beta metabolic process GO:0050435 9.26 ACE REN
9 cellular protein metabolic process GO:0044267 9.26 ALB CST3 F2 NPPA
10 angiotensin maturation GO:0002003 9.16 ACE REN
11 regulation of blood pressure GO:0008217 8.92 ACE EDN1 NPPA REN

Molecular functions related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 8.92 EDN1 F2 NPPA REN

Sources for Hepatorenal Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....